IceCure Medical Ltd. (ICCM) Stock Price, Financials & Summary

Price chart

Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3

Key dataNov 3, 2026

Open$0.84

From 52W high−96.48%

Volume148895.00

Market cap$2.64M

P/E (TTM)—

P/S (TTM)0.7x

Div yield—

Key dataNov 3, 2026

Open

$0.84

From 52W high

−96.48%

Volume

148895.00

Market cap

$2.64M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.6x

P/E (TTM)

—

RSI (14)

16.0

MomentumView details →

1D Return

−8.52%

YTD Return

−95.69%

SummaryUpdated Jun 1, 2026

IceCure Medical Ltd (NASDAQ:ICCM) is an Israeli medical device company founded in 2006 and headquartered in Caesarea, Israel. The company went public on NASDAQ in August 2021. IceCure specializes in developing and commercializing cryoablation technology, which uses extreme cold to destroy diseased tissue, particularly for cancer treatment. The company's flagship product, the ProSense system, is designed to treat breast tumors through minimally invasive cryoablation procedures. IceCure is currently awaiting FDA approval for its ProSense system in the United States while maintaining commercial operations in international markets.

Ask drillr about IceCure Medical Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.6x

EV/Sales

−2.4x

P/S (TTM)

0.7x

P/B (TTM)

0.2x

ProfitabilityView details →

Gross Margin

36.10%

Net Margin

−427.67%

EBITDA Margin

−416.49%

ROE (TTM)

−141.90%

ROA (TTM)

−95.33%

Asset Turnover

0.25x

GrowthView details →

Revenue YoY

+41.62%

EPS YoY

−79.42%

FCF YoY

−14.91%

Revenue CAGR 3Y

+3.08%

EPS CAGR 3Y

+21.11%

EBITDA YoY

−5.76%

MomentumView details →

1D Return

−8.52%

YTD Return

−95.69%

1Y Return

−96.37%

RSI (14)

16.0

vs 50D SMA

−50.54%

vs 200D SMA

−89.79%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

2.87x

Quick Ratio

2.44x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.54

EPS Surprise

−1.32%

Beats (12Q)

3/12

Next Q EPS Est

−$1.15

Avg Surprise (4Q)

−35.33%

Rev Surprise

−35.51%

Financials snapshotView financials →

Revenue (TTM)

3.95M

Net Income (TTM)

−16.88M

Op. CF (TTM)

−16.32M

Next earningsNov 18, 2026 →

Latest newsMore news →

IceCure Medical announced that the first two patients were enrolled at two U.S. clinical sites in its post-marketing ChoICE Study evaluating ProSense cryoablation for low-risk breast cancer.15d ago

IceCure Medical added Legacy Health in Portland, Oregon, including its Legacy Medical Group–Surgical Oncology at Good Samaritan Medical Center, as a new U.S. clinical site for its post-marketing ChoICE Study evaluating ProSense cryoablation in low-risk breast cancer.29d ago

Similar companies

Nuwellis, Inc.NUWE Adagio Medical Holdings, Inc.ADGM INVO Fertility, Inc.IVF 20/20 Biolabs, Inc. Common StockAIDX Autonomix Medical, Inc. Common StockAMIX Holdco Nuvo Group D.G Ltd. Ordinary SharesNUVO Find similar companies →

Latest newsMore news →

IceCure Medical announced that the first two patients were enrolled at two U.S. clinical sites in its post-marketing ChoICE Study evaluating ProSense cryoablation for low-risk breast cancer.15d ago IceCure Medical added Legacy Health in Portland, Oregon, including its Legacy Medical Group–Surgical Oncology at Good Samaritan Medical Center, as a new U.S. clinical site for its post-marketing ChoICE Study evaluating ProSense cryoablation in low-risk breast cancer.29d ago IceCure Medical received regulatory approval to market its ProSense cryoablation system in China.55d ago